Teknova to Participate in Upcoming Investor Conference
Alpha Teknova, Inc. (Nasdaq: TKNO), a leader in critical reagents for drug therapies and vaccines, will join the Morgan Stanley 20th Annual Global Healthcare Conference from September 12-14, 2022, in New York.
On September 13, 2022, at 7:20 AM ET, CEO Stephen Gunstream and CFO Matt Lowell will engage in a fireside chat discussing company highlights, product portfolio, and market trends. A live audio webcast will be available on Teknova's Investor Relations website for 90 days post-event.
- None.
- None.
HOLLISTER, Calif., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading provider of critical reagents for the discovery, development, and commercialization of drug therapies, novel vaccines, and molecular diagnostics, today announced that the Company will participate in the following upcoming investor conference.
Morgan Stanley 20th Annual Global Healthcare Conference
September 12-14, 2022
New York, NY
Stephen Gunstream, Teknova’s President and Chief Executive Officer, and Matt Lowell, Teknova’s Chief Financial Officer, will participate in a fireside chat at 7:20 a.m. ET, on Tuesday, September 13, 2022. Gunstream and Lowell plan to discuss Company highlights, their product portfolio, market trends, key growth drivers, and long-term market opportunities.
The live audio webcast for this conference may be accessed from the Investor Relations section of the Company’s website: https://ir.teknova.com/. The webcast and transcript will be available on the Company’s website for approximately 90 days after the event.
About Teknova
Teknova is expediting clinical breakthroughs in life sciences by providing custom products and reagents for drug therapies, novel vaccines, and molecular diagnostics. With a focus on agility and customization, Teknova delivers research-grade and GMP products, including cell culture media and supplements, protein and nucleic acid purification buffers, and molecular biology reagents for a multitude of established and emerging applications, including cell and gene therapy, mRNA therapeutics, genomics, and synthetic biology. Teknova's proprietary processes enable the manufacture and delivery of high-quality, custom, made-to-order products with short turnaround times and at scale across all stages of development, including commercialization.
FAQ
What event will Alpha Teknova participate in September 2022?
When is Teknova's fireside chat at the Morgan Stanley conference?
Who will represent Teknova at the investor conference?
Where can I access the webcast for Teknova's conference participation?
How long will the Teknova webcast be available after the event?
